Department of Orthopaedic Surgery, St Elisabeth Hospital, Tilburg, the Netherlands.
Am J Sports Med. 2011 Jun;39(6):1200-8. doi: 10.1177/0363546510397173. Epub 2011 Mar 21.
Platelet-rich plasma (PRP) has been shown to be a general stimulation for repair and 1-year results showed promising success percentages.
This trial was undertaken to determine the effectiveness of PRP compared with corticosteroid injections in patients with chronic lateral epicondylitis with a 2-year follow-up.
Randomized controlled trial; Level of evidence, 1.
The trial was conducted in 2 Dutch teaching hospitals. One hundred patients with chronic lateral epicondylitis were randomly assigned to a leukocyte-enriched PRP group (n = 51) or the corticosteroid group (n = 49). Randomization and allocation to the trial group were carried out by a central computer system. Patients received either a corticosteroid injection or an autologous platelet concentrate injection through a peppering needling technique. The primary analysis included visual analog scale (VAS) pain scores and Disabilities of the Arm, Shoulder and Hand (DASH) outcome scores.
The PRP group was more often successfully treated than the corticosteroid group (P < .0001). Success was defined as a reduction of 25% on VAS or DASH scores without a reintervention after 2 years. When baseline VAS and DASH scores were compared with the scores at 2-year follow-up, both groups significantly improved across time (intention-to-treat principle). However, the DASH scores of the corticosteroid group returned to baseline levels, while those of the PRP group significantly improved (as-treated principle). There were no complications related to the use of PRP.
Treatment of patients with chronic lateral epicondylitis with PRP reduces pain and increases function significantly, exceeding the effect of corticosteroid injection even after a follow-up of 2 years. Future decisions for application of PRP for lateral epicondylitis should be confirmed by further follow-up from this trial and should take into account possible costs and harms as well as benefits.
富血小板血浆 (PRP) 已被证明可普遍刺激修复,且 1 年的结果显示出有希望的成功率。
本试验旨在确定 PRP 与皮质类固醇注射治疗慢性外侧肱骨髁炎的疗效,随访时间为 2 年。
随机对照试验;证据水平,1 级。
该试验在 2 家荷兰教学医院进行。100 例慢性外侧肱骨髁炎患者随机分为富含白细胞的 PRP 组(n=51)或皮质类固醇组(n=49)。通过中央计算机系统进行随机分组和分组。患者接受皮质类固醇注射或自体血小板浓缩物注射,采用胡椒针刺技术。主要分析包括视觉模拟评分 (VAS) 疼痛评分和上肢功能障碍 (DASH) 评分。
PRP 组的治疗成功率高于皮质类固醇组(P<0.0001)。成功定义为 2 年后 VAS 或 DASH 评分降低 25%且无需再次干预。当比较基线 VAS 和 DASH 评分与 2 年随访时的评分时,两组在整个时间内均显著改善(意向治疗原则)。然而,皮质类固醇组的 DASH 评分恢复到基线水平,而 PRP 组的 DASH 评分显著改善(实际治疗原则)。PRP 无相关并发症。
用 PRP 治疗慢性外侧肱骨髁炎可显著减轻疼痛并提高功能,甚至在 2 年的随访后效果优于皮质类固醇注射。未来应用 PRP 治疗外侧肱骨髁炎的决策应通过本试验的进一步随访来证实,并应考虑可能的成本、危害和益处。